<DOC>
	<DOCNO>NCT02024971</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy long-term use pioglitazone/metformin hydrochloride combination tablet routine clinical setting patient type 2 diabetes mellitus therapy pioglitazone hydrochloride combine metformin hydrochloride consider suitable .</brief_summary>
	<brief_title>Special Drug Use Surveillance Pioglitazone/Metformin Hydrochloride Combination Tablets Survey Long-term Use Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This special drug use surveillance ( survey long-term use ) design investigate safety efficacy long-term use pioglitazone/metformin hydrochloride combination tablet ( Metact Combination Tablets ) patient type 2 diabetes mellitus routine clinical setting . The following item also study : 1 . The effect safety efficacy cause change administration method metformin hydrochloride associate switch Metact Combination Tablets 2 . The effect compliance associate switch Metact Combination Tablets 3 . Safety efficacy patient show inadequate response pioglitazone hydrochloride switch Metact Combination Tablets The planned sample size 1000 participant . The usual adult dosage one tablet Metact administer orally daily breakfast ( 15 mg/500 mg 30 mg/500 mg pioglitazone/metformin hydrochloride ) . &lt; Precautions Related Dosage Administration &gt; Edema due pioglitazone administration report comparative frequency woman . Therefore , preferable vigilant edema start Metact Combination Tablets dosage equivalent 15 mg pioglitazone daily administer study drug woman .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients type 2 diabetes mellitus physician conclude therapy pioglitazone hydrochloride combine metformin hydrochloride suitable longterm treatment Metact Combination Tablets consider necessary . Patients pioglitazone hydrochloride metformin hydrochloride contraindicate . 1 . Patients cardiac insufficiency history cardiac insufficiency 2 . Patients follow condition ( ) Patients history lactic acidosis ( ii ) Dialysis patient ( include peritoneal dialysis ) ( iii ) Patients cardiovascular condition shock , cardiac insufficiency , myocardial infarction , pulmonary embolism ; patient severely impaired pulmonary function ; patient condition foster susceptibility hypoxemia ( iv ) Patients excessive alcohol consumption ( v ) Patients dehydration ( vi ) Patients gastrointestinal disorder diarrhea vomit ( vii ) Elderly patient 3 . Patients renal impairment ( include mild renal impairment ) 4 . Patients hepatic impairment 5 . Patients severe ketosis , diabetic coma precoma , type I diabetes mellitus 6 . Patients severe infection , severe trauma , pre postoperative patient 7 . Patients malnourish , starve , debilitate , pituitary gland insufficiency adrenal gland insufficiency 8 . Patients history hypersensitivity ingredient Metact Combination Tablets biguanides 9 . Pregnant potentially pregnant woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>